Pipeline Database
UB088
Amoxicillin and Clavulanate Potassium for Suspension (4:1)
UB088
ProductAmoxicillin and Clavulanate Potassium for Suspension (4:1)
Strength250mg/62.5mg
IndicationsRespiratory tract infection; Acute bacterial otitis media; Sinusitis; Skin and soft tissue infection; Urinary tract infection
TherapeuticsInfectious Diseases
GMPCN - NMPA; US - FDA
RegistrationChina
ModalitiesSmall Molecule
Exclusive Summary
- - Fully off-patent with broad generic entry; FDA-GMP plus TT offering enables rapid access across markets.
- - High, steady pediatric demand across AOM/sinusitis/CAP/bite wounds drives large recurring volumes.
- - Listed on WHO EML/EMLc and recommended by major guidelines (IDSA/AAP) as first-line or preferred/alternative therapy.
- - Pediatric dry suspension carries stability/palatability barriers, leaving supply gaps for high-quality products.
- - Mature generics typically deliver 70–90% price savings vs Augmentin, winning in tenders and retail.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →